GraniteShares Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

GraniteShares Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$698K	Buy	+1,120	New	+$762K	0.45%	63
2024 Q4	–	Sell	-1,109	Closed	-$1.17M	–	118
2024 Q3	$1.17M	Sell	1,109 -121	-10%	-$135K	0.79%	55
2024 Q2	$1.29M	Buy	1,230 +102	+9%	+$98.9K	0.43%	55
2024 Q1	$1.09M	Sell	1,128 -9	-0.8%	-$8.56K	0.57%	59
2023 Q4	$999K	Sell	1,137 -176	-13%	-$145K	0.9%	56
2023 Q3	$1.08M	Buy	1,313 +1,004	+325%	+$789K	1.01%	51
2023 Q2	$222K	Sell	309 -21	-6%	-$16.2K	0.2%	100
2023 Q1	$271K	Sell	330 -8	-2%	-$6.03K	0.24%	100
2022 Q4	$244K	Sell	338 -57	-14%	-$42.1K	0.2%	128
2022 Q3	$272K	Sell	395 -54	-12%	-$34K	0.22%	111
2022 Q2	$265K	Sell	449 -13	-3%	-$8.45K	0.19%	118
2022 Q1	$322K	Sell	462 -49	-10%	-$31K	0.17%	130
2021 Q4	$322K	Buy	+511	New	+$314K	0.15%	139

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GraniteShares Advisors's REGN Position: Q2 2026 in Review

GraniteShares Advisors opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 1,120 shares worth $698K. The stake represents 0.45% of the portfolio and ranks #63 among its holdings. This is a return to the name: GraniteShares Advisors previously reported a position in REGN as recently as Q3 2024.

GraniteShares Advisors first reported a position in REGN in Q4 2021 and has held it in 13 quarters since. The position peaked at $1.29M in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

GraniteShares Advisors held 1,120 shares of Regeneron Pharmaceuticals worth $698K as of Q2 2026.
Regeneron Pharmaceuticals was a new GraniteShares Advisors position in Q2 2026.
Regeneron Pharmaceuticals made up 0.45% of GraniteShares Advisors's portfolio in Q2 2026, its #63 holding.
GraniteShares Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
GraniteShares Advisors's Regeneron Pharmaceuticals position peaked at $1.29M in Q2 2024.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on GraniteShares Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.